{{knowledge objective
|Identifiant=OIC-027-32-B
|Item_parent=Prevention of foetal risks: infection, drugs, toxic substances, irradiation
|Item_parent_short=Prevention of foetal risks: infection, drugs, toxic substances, irradiation
|Rank=B
|Intitulé=Médicaments et grossesse : connaître les conséquences des principaux médicaments à risque
|Description=None
|Rubric=Positive diagnosis
|Contributors=Alexandre Vivanti, Philippe Deruelle
|Order=32}}

{| class="wikitable"
|'''Family'''
|'''INN (trade name)'''
|'''Type of malformation(s)'''
|'''Procedure'''
|-
|Vitamin A derivatives
|Isotretinoin

(Roaccutane<sup>®</sup>, Acnetrait<sup>®</sup>, Curacne<sup>®</sup>, Procuta<sup>®</sup>)

Acitretin

(Soriatane<sup>®</sup>)
|CNS malformations, outer ear, heart

Skeletal malformations
|Prescription of exclusive oral contraception, provision of a follow-up booklet

If pregnant, CPDPN to discuss IMG

Pregnancy contraindicated within 2 years of stopping treatment
<br />Pregnancy
|-
|Thymoregulator
|Lithium (Téralithe<sup>®</sup>)
|Cardiac malformations (ductus arteriosus, IVC) 4-8 %.
|In case of pregnancy on lithium, follow-up in CPDPN and foetal echocardiography.
|-
|Oral anticoagulants, antivitamins K
|Warfarin (Coumadine<sup>®</sup>)
|Warfarin fetal syndrome 4-6 %.

Facial dysmorphia with short or absent OPN, hypoplasia of the last phalanges of the extremities, premature bone calcifications

Cerebral anomalies 2% (microcephaly, hydrocephaly, optic atrophy)
|Fetal brain ultrasound and MRI to look for abnormalities

Prevention: replacement with LMWH for pregnancy

No reason to refer patients for abortion
|-
|Anti-epileptic drugs
|Sodium valproate (Depakine<sup>®</sup>), carbamazepine (Tegretol<sup>®</sup>)
|Risks from ''in utero'' exposure during pregnancy:

- spina bifida (6.5 ''vs'' 0.3 ‰; OR [''Odds Ratio''<nowiki>]: 18.8, CI 95% : [8.4-42.3])</nowiki>

- VIC (11.2 ''vs''<nowiki> 2.7 ‰; OR: 4.0 [2.2-7.5])</nowiki>

- CIA (19.1 ''vs''<nowiki> 1.9 ‰; OR: 9.1 [5.6-14.8])</nowiki>

- Pulmonary artery atresia (2.2 ''vs''<nowiki> 0.1 ‰; OR: 26.2 [3.1-96.6])</nowiki>.

- hypoplasia of the left ventricle (2.2 ''vs''<nowiki>0.1 ‰; OR: 17.9 [2.1-65.5])</nowiki>.

- Cleft palate (3.4 ''vs''<nowiki>0.7 ‰; OR: 5.2 [1.1-15.2])</nowiki>

- anorectal atresia (3.4 ''vs''<nowiki> 0.3‰; OR: 11.0 [2.3-32.4])</nowiki>

- hypospadias (22.7 ''vs''<nowiki>4.8 ‰; OR: 4.7 [2.3-9.7])</nowiki>

- Pre-axial polydactyly (2.2 ''vs''<nowiki> 0.2 ‰; OR: 10.8 [1.3- 39.5])</nowiki>.

Others on Depakin<sup>®</sup>: thrombocytopenia, reduced platelet activity, fibrinogen and coagulation factors.
|Depakine<sup>®</sup>: essential preconception consultation coupled with a neurological opinion.

Refer to CPDPN in case of exposure and usual prevention with folic acid 5 mg/d

Ultrasound for abnormalities including echocardiography

Blood determination of AFP, increased, during serum screening for trisomy 21 (if done in the 2nd<sup>trimester</sup>), suggestive of a neural tube closure anomaly
|-
|Prostaglandin 1 analogue (PGE1)
|Misoprostol (Gymiso<sup>®</sup>, Misoone<sup>®</sup>)
|Moebius syndrome: central paralysis of the 6th</sup>and 7th</sup> cranial pairs, retrognathia, trismus, distal limb abnormalities.

Cause: poor foetal vascularisation following induction of uterine contractions in the 1st<sup>trimester</sup> (FC)

MFIU in the 3rd<sup>trimester
<br />
|Ultrasound for abnormalities

Indication for monitoring in CPDPN
|-
|Immunosuppressant
|Mycophenolate (Cellcept<sup>®</sup>, Myfortic<sup>®</sup>)
|50% risk of SCF

Risk of malformation of the external ear, cleft lip and palate or nostril, micrognathia, etc.
|A patient on mycophenolate should have a preconception consultation to change treatment before conception.

If the patient becomes pregnant, she should consult a doctor to adapt the treatment quickly.
|-
|Cancer drugs
|Methotrexate (Ledertrexate<sup>®</sup>, Imeth<sup>®</sup>)
|Folic acid antagonists: craniostenosis, facial dysmorphia, IUGR, congenital heart disease, FC, etc.
|Warning of the significant risk of termination of pregnancy
|-
|Synthetic antithyroid drugs
|Carbimazole, (Neo-Mercazole<sup>®</sup>)

PTU (propylthio-uracil: Propylex<sup>®</sup>)
|Scalp aplasia, choanal atresia, oesotracheal fistula and, more rarely, facial dysmorphia and even abdominal wall damage such as omphalocele and gastroschisis.

Goitres observed in foetuses of treated mothers but not always related to PTU but also to basedow's disease (Track)
|Replace carbimazole in the 1st<sup>term</sup> with PTU, and regularly monitor maternal thyroid function (T4l, T3l, TSHus).

It can then be taken back because of the maternal liver damage described for PTU

Monitor the foetal thyroid under treatment, especially if TRAK is positive

Risk of maternal hepatotoxicity, so carbimazole should be discussed from the 2nd<sup>trimester</sup>.
|-
|Virostatics
|Ribavirin (Copegus<sup>®</sup>, Rebetol<sup>®</sup>)

Efavirenz (Sustiva<sup>®</sup>)
|In animals (dose-dependent teratogenicity): malformations of the face (skull, palate, eyes, jaw), limbs, digestive tract and bones.

Risk of non-closure of the neural tube: 0.07%.
|Prescription under contraception

If a pregnancy occurs, organise follow-up at the CPDPN

Avoid in the 1<sup>st</sup> trimester
|}


'''312. [[Prevention of foetal risks SD-312|Prevention of foetal risks]]''''

'''340 [[Voluntary or involuntary intake of a toxic or potentially toxic drug SD-340|Voluntary or involuntary intake of a toxic or potentially toxic drug]]''''

'''348. [Suspicion of an adverse drug reaction or an adverse drug treatment SD-348|Suspicion of an adverse drug reaction or an adverse drug treatment]'''''

'''352. [[Explaining treatment to the patient (adult/child/adolescent) SD-352|Explaining treatment to the patient (adult/child/adolescent)]]'''''